Malta - English - Medicines Authority

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 500 mg - all other therapeutic products

Israel - English - Ministry of Health

pharma medis - sevoflurane - liquid - sevoflurane 100 %v/v - sevoflurane - sevoflurane - general inhalation anesthetic.

European Union - English - EMA (European Medicines Agency)

teva pharma b.v.  - clopidogrel (as hydrobromide) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome: non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - voriconazole -

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - caspofungin -

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - caspofungin -

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - linezolid -

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - european house dust mite extract, quantity: 6 sq-hdm; american house dust mite extract, quantity: 6 sq-hdm - tablet - excipient ingredients: gelatin; sodium hydroxide; purified water; mannitol - allergic rhinitis acarizax is indicated for the treatment of house dust mite (hdm) allergic rhinitis not well controlled despite use of symptom relieving medication in adults and adolescents (? 12 years). allergic asthma acarizax is indicated for the treatment of hdm allergic asthma not well controlled by inhaled corticosteroids and associated with hdm allergic rhinitis in adults. patients? asthma status should be carefully evaluated before the initiation of treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - ephedrine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - european house dust mite extract, quantity: 5 ir/ml; american house dust mite extract, quantity: 5 ir/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; phenol; sodium chloride; water for injections; mannitol - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.